Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Different expression of EZH2, BMI1 and Ki67 in low and high grade neuroendocrine tumors of the lung

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. A blood biomarker for monitoring response to anti-EGFR therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Enhancer of Zeste Homolog 2 (EZH2) and B lymphoma Mo-MLV Insertion region 1 polycomb ring finger (BMI1) are involved in malignant transformation of many human carcinomas. Still, in neuroendocrine tumors of the lung (NELT) their expression pattern is largely unknown. This study evaluated their expression in 96 NELT and correlated it to clinical features including survival.
Original languageEnglish
JournalCancer Biomarkers
Volume11
Issue number2-3
Pages (from-to)123-8
Number of pages6
ISSN1574-0153
DOIs
Publication statusPublished - 2012

ID: 36850508